Dermatology Times Monthly FDA and Pipeline Review: October 2026
Published . Updated .
Key takeaways
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.
Directly affected
- No company is named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story.
- LLY Eli Lilly and+25.0% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
- JNJ Johnson & Johnson+9.5% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
- PFE Pfizer+6.0% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
- MRK Merck+3.7% 30d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLV | -2.11% | -0.32% | base | -0.42% | after close | after close | after close |
| XBI | -5.02% | +0.41% | base | -3.25% | after close | after close | after close |
| LLY | -4.90% | -1.77% | base | -0.54% | after close | after close | after close |
| JNJ | -2.81% | +0.64% | base | +1.15% | after close | after close | after close |
| PFE | +1.46% | -0.70% | base | -2.11% | after close | after close | after close |
| MRK | -0.21% | +1.03% | base | -0.17% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Dermatology Times Monthly FDA and Pipeline Review: October 2026 Dermatology Times
Source: Dermatology Times
How Select Sector Spdr Tr (XLV) moved after the last 4 energy shocks
Across 4 earlier stories, Select Sector Spdr Tr (XLV) the next day averaged -0.38%. The largest gain was -0.38% and the largest drop was -0.38%, from 4 prices.
| Company | When | Average | Largest gain | Largest drop | Prices |
|---|---|---|---|---|---|
| Select Sector Spdr Tr (XLV) | the next day | -0.38% | -0.38% | -0.38% | 4 |
| Spdr Series Trust (XBI) | the next day | -2.49% | -2.49% | -2.49% | 4 |
| Eli Lilly (LLY) | the next day | -0.16% | -0.16% | -0.16% | 4 |
| Johnson & Johnson (JNJ) | the next day | +0.99% | +0.99% | +0.99% | 4 |
Price since this story was published: Select Sector Spdr Tr (XLV)
| Company | When | Move | Status |
|---|---|---|---|
| Johnson & Johnson (JNJ) | that day | +1.15% | final price |
| Johnson & Johnson (JNJ) | three days earlier | +0.64% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -2.81% | final price |
| Eli Lilly (LLY) | that day | -0.54% | final price |
| Eli Lilly (LLY) | three days earlier | -1.77% | final price |
| Eli Lilly (LLY) | five days earlier | -4.90% | final price |
| Merck (MRK) | that day | -0.17% | final price |
| Merck (MRK) | three days earlier | +1.03% | final price |
| Merck (MRK) | five days earlier | -0.21% | final price |
| Pfizer (PFE) | that day | -2.11% | final price |
| Pfizer (PFE) | three days earlier | -0.70% | final price |
| Pfizer (PFE) | five days earlier | +1.46% | final price |
| Spdr Series Trust (XBI) | that day | -3.25% | final price |
| Spdr Series Trust (XBI) | three days earlier | +0.41% | final price |
| Spdr Series Trust (XBI) | five days earlier | -5.02% | final price |
| Select Sector Spdr Tr (XLV) | that day | -0.42% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | -0.32% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -2.11% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 69 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 36 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 43 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 48 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 69 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 83 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 49 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 85 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Companies in energy around Select Sector Spdr Tr (XLV)
Companies tied to this story
- XLV Select Sector Spdr Tr
In “Dermatology Times Monthly FDA and Pipeline Review: October 2026,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
- XBI Spdr Series Trust
Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence in the 12 Nov 2026 story “Dermatology Times Monthly FDA and Pipeline Review: October 2026.” Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
- LLY Eli Lilly
In “Dermatology Times Monthly FDA and Pipeline Review: October 2026,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
- JNJ Johnson & Johnson
Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence in the 12 Nov 2026 story “Dermatology Times Monthly FDA and Pipeline Review: October 2026.” Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
- PFE Pfizer
For “Dermatology Times Monthly FDA and Pipeline Review: October 2026,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
- MRK Merck
For “Dermatology Times Monthly FDA and Pipeline Review: October 2026,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
How energy news reaches Select Sector Spdr Tr (XLV)
Select Sector Spdr Tr (XLV) is the company in “Dermatology Times Monthly FDA and Pipeline Review: October 2026,” the 12 Nov 2026 Energy story.
For Select Sector Spdr Tr (XLV), the reason on file says Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
Also listed, Spdr Series Trust (XBI): SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
The price range for Select Sector Spdr Tr (XLV), and the dates in the story
LLY traded between 1228.55 and 1452.66 across 20 sessions. The latest close on file is 1437.79.
A simple score for Select Sector Spdr Tr (XLV)
46 out of 100
“Dermatology Times Monthly FDA and Pipeline Review: October 2026” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.